Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Migraine Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
H-21048416 | N/A |
Unknown status |
Post-Traumatic Headache |
2023-12-31 |
|
H22038923 | N/A |
Completed |
Migraine Disorders |
2023-08-04 |
|
H19065735 | N/A |
Completed |
Headache|Migraine Disorders |
2021-03-19 |
|
H-17011569 | N/A |
Unknown status |
Cluster Headache |
2020-01-01 |